ClinicalTrials.gov ID NCT03746431
Sponsor Fusion Pharmaceuticals Inc.
Local PI Ale Berlin
Conditions:
- Advanced Solid Tumours
- Endometrial Cancer
- Cervical Cancer
- Ovarian Cancer
- Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- HER2-negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Adrenocortical Carcinoma
- Uveal Melanoma
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent).